VLDL binds APOC1 and APOC4

Stable Identifier
R-HSA-8866321
Type
Reaction [binding]
Species
Homo sapiens
Compartment
ReviewStatus
5/5
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Newly formed very low-density lipoprotein (VLDL) released from the liver can acquire lipoproteins in the circulation. Apolipoprotein C-I (APOC1) is a 6.6 kDa apolipoprotein that is synthesised mainly in the liver but also in other tissues. It is a constituent of triglyceride-rich lipoproteins (around 10% of the protein of VLDLs and 2% of HDLs) that slow the circulatory clearance of triglyceride-rich lipoproteins by a variety of mechanisms. As well as binding and inhibiting triglyceride-rich lipoprotein uptake by the very low-density lipoprotein receptor (VLDLR), it can also binds free fatty acids (FAs) in the circulation, reducing their uptake by cells (Shachter 2001, Hansen et al. 2011). A minor constituent of VLDL is apolipoprotein IV (APO4) (Kotite et al. 2003).
Literature References
PubMed ID Title Journal Year
12700345 Human apoC-IV: isolation, characterization, and immunochemical quantification in plasma and plasma lipoproteins

Havel, RJ, Kotite, L, Zhang, LH, Yu, Z, Burlingame, AL

J. Lipid Res. 2003
11353333 Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism

Shachter, NS

Curr. Opin. Lipidol. 2001
21776394 The apolipoprotein C-I content of very-low-density lipoproteins is associated with fasting triglycerides, postprandial lipemia, and carotid atherosclerosis

Björkegren, J, Deguchi, H, Hansen, JB, Mathiesen, EB, Notø, AT, Fernández, JA

J Lipids 2011
Participants
Participates
Orthologous Events
Authored
Reviewed
Created
Cite Us!